CONMED Corporation announced on June 17, 2026 that John E. Gallagher will become Executive Vice President, Chief Financial Officer, and principal financial and accounting officer starting July 15, 2026, succeeding Todd Garner who will remain in an advisory role until November 2, 2026. Gallagher brings nearly three decades of finance leadership experience from healthcare and industrial companies, including senior roles at Certara, Cue Health, and Becton Dickinson. The appointment comes alongside a June 1, 2026 amendment to CONMED's credit agreement that added a US$450,000,000 delayed draw term facility to address its 2.25 percent Convertible Senior Notes due 2026. The company's narrative projects $1.6 billion in revenue and $154.0 million in earnings by 2028, with a fair value estimate of $48.40 per share, representing a 49% upside to its current price. Analysts had previously assumed about 3.5 percent annual revenue growth and US$170.3 million in 2029 earnings, and views on CONMED's risk around rising global healthcare cost controls may shift as the new CFO's priorities become clearer.
CONMED CorporationAppointment of new CFO and credit amendment to address convertible notes, with projected upside.
